帕拉米韦治疗儿童甲型流感病毒感染的临床疗效

Abstract

目的 探讨帕拉米韦在治疗儿童甲型流感病毒感染的临床疗效及安全性.方法 将2016年6月至2017年1月首都医科大学附属北京儿童医院收治的确诊甲型流感患儿共300例,采用前瞻性研究,分为帕拉米韦治疗组(150例)和奥司他韦治疗组(150例).观察两组患儿治疗后发热缓解时间、症状缓解时间及不良反应.结果 帕拉米韦治疗组和奥司他韦治疗组患儿中位症状缓解时间分别为27.9 h和42.7 h,差异具有统计学意义(t = -18.325、P < 0.001);两组患儿中位发热缓解时间分别为17.8 h和22.3 h,差异具有统计学意义(t = -9.365、P < 0.001).两组病例均无并发症发生.帕拉米韦治疗组和奥司他韦治疗组患儿不良反应发生率分别为4.0%和7.3%,差异无统计学意义(χ2=1.349、P = 0.246).两组患儿不良反应均未经特殊处理自行缓解消退.结论 帕拉米韦治疗儿童甲型流感病毒感染可快速有效缓解症状、缩短发热持续时间,安全性及耐受性良好.

Objective To investigate the clinical efficacy and safety of peramivir in the treatment of children with influenza virus infection. Methods Total of 300 children admitted to Beijing Children's Hospital who diagnosed with influenza A were divided into peramivir treatment group (150 cases) and oseltamivir treatment group (150 cases) by prospective study method, from June 2016 to January 2017. The fever remission time, symptom relief time and adverse reaction of patients in the two groups were compared after treatment. Results The median symptom relief time was 27.9 hours of patients in peramivir group and 42.7 hours of patients in oseltamivir group, with significant difference (t = -18.325, P < 0.001). The median fever remission time were 17.8 hours and 22.3 hours of patients in peramivir treatment group and oseltamivir treatment group, with significant difference (t = -9.365, P < 0.001). No complications occurred in patients of the two groups. The adverse reaction rate was 4% of patients in peramivir group and 7.3% of patients in oseltamivir group, with significant difference (χ2= 1.349, P = 0.246). All adverse reactions were self-mitigating without special treatment. Conclusions The use of peramivir for treatment of children with influenza A virus infection could quickly and effectively relieve the symptoms and shorten the duration of fever, with good safety and tolerability.